BDX Becton Dickinson

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Development and marketing of medical devices with focus on patient and medication delivery solutions
• • New emphasis: Remediation and U.S. market return of BD Alaris™ Infusion System post FDA 510(k) clearance July 2023
• • Strategic shift: Proposed combination of Biosciences and Diagnostic Solutions segment with Waters, shareholders to own 39.2% of the combined entity
• • Notable metric: Entry into a December 2024 SEC Order impacting "well-known seasoned issuer" status, affecting debt refinancing capability
• • Unusual fact: Extended transition timelines to 2027-2028 for EU MDR and IVDR compliance causing significant regulatory and operational impacts

Risk Factors

• • FDA Consent Decree on U.S. infusion pump business, risk of manufacturing suspension and significant monetary damages if violated
• • Geopolitical exposure to ongoing conflicts in Ukraine, Middle East, and Asia impacting international operations and supply chains
• • Supply chain dependence on sole-source suppliers for sterilization services and raw materials like oil-based resins amid cost increases and availability risks
• • Competitive threat from emerging technologies such as AI used by rivals and from low-cost manufacturers increasing pricing pressures
• • Debt servicing risk dependent on capital markets and macroeconomic environment affecting ability to refinance or service borrowings

Management Discussion & Analysis

• • Total revenue $23.5B, up 6% YoY driven by Medical segment growth
• • Operating margin 18.9%, down from 20.3% YoY due to higher input costs
• • Medical segment revenue $12.7B, best performer, up 8% YoY; Interventional segment worst, $4.1B, down 3% YoY
• • Operating cash flow $3.2B; share repurchases $800M; dividends paid $600M; capital expenditures $1.1B
• • Management expects moderate revenue growth but warns of supply chain risks and inflationary pressures impacting margins

What are the latest BDX SEC filings in 2026?

Becton Dickinson (BDX) has filed a 10-K annual report on November 25, 2025, a 10-Q quarterly report on May 7, 2026, an 8-K current report on July 22, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did BDX file its most recent 10-K annual report?

Becton Dickinson (BDX) filed its most recent 10-K annual report on November 25, 2025. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view BDX 10-Q quarterly reports?

Becton Dickinson (BDX)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every BDX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has BDX filed recently?

Becton Dickinson (BDX)'s most recent 8-K was filed on July 22, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find BDX insider trading activity (Form 4)?

SignalX aggregates every BDX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does BDX file with the SEC?

Becton Dickinson (BDX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new BDX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Becton Dickinson (BDX).

What is BDX's SEC CIK number?

Becton Dickinson (BDX)'s SEC CIK (Central Index Key) number is 10795. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 10795 to look up all BDX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find BDX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Becton Dickinson (BDX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.